A study of electrolyte disturbances in patients with chronic stable asthma and with asthma attacks  by Mohammad, Hala A. et al.
Egyptian Journal of Chest Diseases and Tuberculosis (2014) 63, 529–534The Egyptian Society of Chest Diseases and Tuberculosis
Egyptian Journal of Chest Diseases and Tuberculosis
www.elsevier.com/locate/ejcdt
www.sciencedirect.comORIGINAL ARTICLEA study of electrolyte disturbances in patients
with chronic stable asthma and with asthma attacks* Corresponding author. Tel.: +20 109617612; fax: +20 862342505.
E-mail addresses: hala_awatef@yahoo.com, hala_awatef@hotmail.
com (H.A. Mohammad).
Peer review under responsibility of The Egyptian Society of Chest
Diseases and Tuberculosis.
Production and hosting by Elsevier
0422-7638 ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
http://dx.doi.org/10.1016/j.ejcdt.2014.03.010Open access under CC BY-NC-ND license.Hala A. Mohammad a,*, Mohammad T. Abdulfttah a, Ali O. Abdulazez a,
Ahmed M. Mahmoud b, Rasha M. Emam aa Pulmonary Department, Faculty of Medicine, Al-Minya University, Egypt
b Biochemistry Department, Faculty of Medicine, Al-Minya University, EgyptReceived 16 February 2014; accepted 5 March 2014
Available online 13 April 2014KEYWORDS
Chronic asthma;
Acute severe asthma;
Hypocalcemia;
Hypokalemia;
Hypomagnesemia;
HyponatremiaAbstract Study Objective: To detect electrolyte disturbances in patients with chronic stable
asthma and patients with asthma exacerbation and to assess the relation between serums electrolyte
levels and pulmonary function parameters and therapeutic agents.
Design: Prospective, hospital-based, cross-sectional study.
Setting: Outpatient chest clinic and in-patient chest department; Alminya university hospitals
Alminya-Egypt.
Patients: One hundred asthmatic patients.
Study methods: Patients were divided into two groups: group I that included 50 patients pre-
sented with chronic stable asthma and group II that included 50 consecutive patients presented with
acute severe asthma. Data collected included sex, age, residence, medication used, clinical examina-
tion, serum level of electrolytes (Na, K, Ca, Mg), and chest X ray, Spirometer was used to assess
pulmonary function according to ATS/ERS standards.
Conclusion: Hypomagnesemia and hypocalcemia were found to be the two most common elec-
trolyte disturbances in patients with chronic stable asthma and also in those with acute asthma
exacerbation. Therapeutic agents used to treat patients with chronic asthma have a role on abnor-
mal electrolyte levels.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction
Asthma is a disease that has become increasingly common
over the last century. It is characterized by chronic lung airway
inﬂammation, increased airway responsiveness and variable
airﬂow obstruction. In recent decades, there has been a marked
increase in asthma prevalence, particularly in westernized
countries [1]. Acute asthma attack or exacerbation can arise
530 H.A. Mohammad et al.any time without any prodromal symptoms and can progress,
either slowly or rapidly, to life-threatening severity [2].
Abnormal electrolyte concentrations in asthma patients can
be attributed to low intake [3–5] or secondary to asthma med-
ications [6,7]. Hypokalemia was the earliest electrolyte distur-
bance reported in acute asthma, and it was related to the use
of b2-agonists and aminophylline therapy [8]. Recently, hypo-
magnesemia, hypophosphatemia, and hypocalcemia have also
been reported after administration of b2-agonists in normal
subjects and in asthmatic patients as well [9]. In acute asthma,
an increase in the urinary excretion of calcium has also been
reported in asthmatic patients treated with IV aminophylline
[10].
Electrolyte levels directly inﬂuence excitability of airway
smooth muscles (ASM) by inﬂuencing the state of ion
exchangers and Na+/K+ pump. Possible hypotheses that
may lead to airway reactivity include a direct effect of electro-
lytes on bronchial smooth muscle contractility as well as po-
tential enhancement of the release of mast cell-derived
inﬂammatory mediators, possibly through airway osmolarity
changes [11].
Hypokalemia, hypomagnesemia, and hypocalcemia are
well-known causes of cardiac arrhythmia [12,13]. In addition,
hypophosphatemia can worsen respiratory failure in severely
ill asthmatic patients through impairment of respiratory mus-
cle performance [14].
This study aimed to detect the frequency of electrolyte (Na,
K, Ca, and Mg) disturbances in asthmatic patients (chronic
stable and acute exacerbation) and their effect on lung func-
tion parameters and to assess whether the therapeutic agents
used to treat chronic asthma have an effect on abnormal elec-
trolyte levels. Also it aimed to detect the efﬁcacy of magnesium
sulfate on clinical and spirometric parameters in patients with
acute asthma exacerbationPatients and methods
The study was approved by the human ethics committee of Al-
minya University Hospital and was conducted in strict compli-
ance with their policy.
This clinical study was a prospective study that included pa-
tients with bronchial asthma who presented as out-patients or
admitted to chest department of Al-Minya University Hospital
over a period of 8 months from 1st of December 2008 to 31th
of January 2010.
The following patients were excluded from the study: (1)
patients with wheezy chest due to causes other than bronchial
asthma, as patients suffering from acute bronchitis, (2) pa-
tients with a history of renal diseases, cardiac diseases, malig-
nant diseases, hyperthyroidism or hypothyroidism, (3)
asthmatic smokers, pregnant women, alcohol abuse and diure-
tic use.
Asthmatic patient was diagnosed by clinical history, physi-
cal examination and American Thoracic Society criteria of
reversibility of FEV1 or peak expiratory ﬂow >12% and
P200 mL and diurnal variations of peak expiratory ﬂow rate
>20% [15].
While attending the asthma clinic, information concerning
age, sex, duration and severity of asthma, and details of
current drug therapy used for management of asthma was
obtained from each asthmatic patient.Spirometry tests (PFTs) which, included forced vital capac-
ity (FVC), forced expiratory volume in 1 s (FEV1), (FEV1/
FVC) and peak expiratory ﬂow rate (PEFR) were done for
all patients using 2130 spirometer Vmax, Sensoromedicus.
Laboratory investigations for biochemical parameters; serum
K, Na, and Ca were measured by using automated chemistry
analyzer (Thermo Electron, model Kone lab 20i, Finland).
Magnesium level in serum was measured by magnesium kit liq-
uicolor photometric colorimetric test. Contents of the kits in-
clude Reagent (RGT) and Standard (STD) magnesium
2.5 mg/dL.
Calculation of magnesium concentration = 2.50 · Absorbed
sample/Absorbed STD (mg/dl) [15]. Magnesium level was
measured by using (SPEKOL 11, Germany). Normal serum
Na level is 135-145 mEq/L. Normal serum K level is
3.5–5.5 mEq/L. Normal serum ionized Ca++ level is
1.07-1.27 mg/dl .Normal serum Mg level by the used kits is
1.9-2.5 mg/dl [16].
The patients in this work were divided into 2 groups
according to the predominating signs and symptoms;
1. Group I [include 50 patients with stable bronchial asthma].
These patients were subdivided according to asthma sever-
ity into 3 groups based on the level of symptoms, airﬂow
limitation and lung function [17]; group Ia includes 10
patients of mild persistent asthma with FEV1P 80%,
group Ib includes 19 patients of moderate persistent asthma
with FEV1 60-80%, group Ic includes 21 patients of severe
persistent asthma with FEV1 6 60%.
2. Group II with acute asthmatic attack includes 50 patients
and have the criteria of severe asthma exacerbation accord-
ing to GINA 2008 classiﬁcation of asthma exacerbation
severity. They received slow infusion of 2gm MgSo4 on
200 cc saline and 20 of them were re-evaluated clinically,
by spirometry and laboratory investigations 1/2 hour after
receiving the medication.
Statistical methodology
Analysis of data was done by IBM computer using SPSS
(statistical program for social science version 20) as follows:
Description of quantitative variables as mean, SD
 Description of qualitative variables as number and
percentage.
 Chi-square test was used to compare qualitative variables
between groups.
 Z test of proportion was used to compare two percentages.
 Unpaired t-test was used to compare two groups as regards
quantitative variables.
 Paired t-test was used to compare quantitative variables
before and after treatment in one group, and P values less
than 0.05 were considered signiﬁcant.
Results
Table 1 summarizes the main characteristics of each group;
group I that included 50 patients (16 males and 34 females)
presented with stable bronchial asthma patients and group II
that included 50 consecutive patients (19 males and 31 females)
Table 1 Distribution of the main characteristics of the asthmatic patients in both groups.
Patients with chronic stable asthma (50) Patients with acute asthma exacerbation (50) P value
Age 35.56 ± 6.33 35.54 ± 6.39 0.98
Sex
Male 16 (32%) 31 (62%) 0.19
Female 34 (68%) 19 (38%)
Duration of symptoms 8.38 ± 6.52 10.14 ± 6.83 0.19
Electrolyte levels
Magnesium (mg/dl) 1.83 ± 0.44 1.12 ± 0.83 0.0001*
Potassium (mEq//l) 3.9 ± 0.84 3.87 ± 0.71 0.04*
Sodium (mEq//l) 144.58 ± 6.38 141.87 ± 3.31 0.7
Calcium (mg/dl) 1.08 ± 0.01 1.09 ± 0.18 0.5
Electrolyte disturbance
No 16 (32%) 1(2%) 0.0002*
One 20 (40%) 20 (40%) 0.8
Two 14 (28%) 23 (46%) 0.09
Three 0 (0%) 6 (12%) 0.03*
Type electrolyte disturbance
Hyponatremia 2 (4%) 1 (2%) 0.9
Hypokalemia 21 (42%) 27 (54%) 0.3
Hypocalcemia 0 (0%) 11 (22%) 0.0001*
Hypomagnesemia 25 (50%) 46 (92%) 0.0001*
* Signiﬁcant P< 0.05.
Table 2 The relation between electrolyte disturbance and severity of asthma in group I.
Mild persistent
asthma (11)
Moderate persistent
asthma (23)
Severe persistent
asthma (16)
P value
Hypomagnesemia 6(54.5%) 10(43.5%) 9(56.2%) 0.6
Hypokalemia 1(9.1%) 11(47.8%) 9(56.2%) 0.03*
Hyponatremia 0(0.0%) 1 (4.3%) 1(6.2%) 0.7
Hypocalcemia 0(0.0%) 0(0.0%) 0(0.0%) –
* Signiﬁcant P <0.05.
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comparable in each group (35.5 ± 6.3 years for both). Females
represent 68% of patients with chronic stable asthma and 38%
of patients with acute asthma exacerbation. Electrolyte distur-
bances were found to be signiﬁcantly more frequent in asth-
matic patients with acute attacks (98%) than chronic stable
asthmatics (68%).
In group I, the highest proportion of electrolyte disturbance
was for magnesium (50%), while the lowest proportions were
for sodium (4%) and calcium (0%). In group II; the highest
proportion of electrolyte disturbance was for magnesium
(92%), while the lowest proportion was for sodium (2%).
Hypomagnesemia and hypocalcaemia were signiﬁcantly more
prevalent in group II patients (acute attacks).
As regards asthma severity in group I, electrolyte distur-
bances were more frequent in patients with moderate and se-
vere persistent asthma, than in those with mild persistent
asthma with a signiﬁcant value for hypokalemia (p< 0.05%)
(Table 2).
As in Table 3, there was an increased frequency of dis-
turbed electrolytes with chronic asthma medications, namely
b2-agonists, steroids, and thiophylline. Hypomagnesemia and
hypokalemia were found signiﬁcantly more in asthmatic pa-
tients who used a combined therapy.Table 4 shows that magnesium sulfate infusion in patients
with acute asthma exacerbation caused a highly signiﬁcant
improvement in all parameters of spirometry.Discussion
In this study, the prevalence of electrolyte disturbance in pa-
tients with asthma was common and reached up to 68% in
chronic stable asthma and a higher percentage in acute severe
asthma (98%). Omar [18] found also that electrolyte distur-
bance is common and present in 43% of ninety three consecu-
tive patients with chronic stable asthma.
Contrary to our expectation, hypomagnesemia rather than
hypokalemia and hypocalcaemia was found to be the most
common electrolyte disturbance in patients with chronic stable
asthma, and in those with acute attacks, with a prevalence of
50% and 92%, in both groups respectively. The mean Mg va-
lue of patients with stable bronchial asthma was 1.8 ± 0.4 mg/
dL. Khosrow et al. [19] reported that hypomagnesemia oc-
curred in 40.5% of the chronic stable asthmatic patients and
the mean Mg value in those patients was 1.85 ± 0.28 mg/dL.
In other studies, Omer [18] and Emad et al. [20] found hypo-
magnesemia in lower frequencies among patients with stable
Table 3 The relation between therapeutic agents and electrolyte disturbances in both studied groups.
Groups medication Group I Group II
Hypo-magnesemia (25) Hypo-kalaemia (21) Hypomagnesemia (46) Hypo-kalemia (27) Hypocalcemia (11)
Mono-therapy
B agonist 4 (16%) 2 (9.5%) 4 (8.7%) 2(7.4%) 0(0%)
Combined therapy
B agonist& steroid 7(28%) 4(19.0%) 5 (8.6%) 4(14.8%) 3 (27.3%)
B agonist & theophylline 4(16%) 2(9.5%) 7(15.2%) 3(11.1%) 2(18.2%)
More than two drug 10(40%) 13(61.9%) 30 (63%) 18(66.7%) 6(54.5%)
Mono-therapy 4 (16%) 2 (9.5%) 4 (8.7%) 2(7.4%) 0(0%)
Combined therapy 21(84% 19 (90.5%) 42(91.3%) 25(92.6%) 11(100%)
P-value 0.0001* 0.0001* 0.0001* 0.0001* 0.0001*
* Signiﬁcant P- <0.05.
Table 4 The changes in pulmonary function parameters
before and after Mg sulfate infusion in group II.
Before Mg
sulfate infusion
After Mg
sulfate nfusion
P value
FVC% 54.9 ± 12.6 63.1 ± 16.5 0.0001*
FEV1% 33.6 ± 9.4 38.7 ± 12.2 0.0001*
PEFR% 27.9 ± 10.5 32.5 ± 13.5 0.0001*
FEF25-75% 15.4 ± 9.26 18.2 ± 10.03 0.002*
Serum Mg 1.1 ± 0.8 2 ± 0.4 0.0001*
* Signiﬁcant P <0.05.
532 H.A. Mohammad et al.bronchial asthma with a prevalence of 27% and 31.7%
respectively.
In our study, a higher incidence of asthma severity and
exacerbation with low serum magnesium levels than in asth-
matic patients with normal levels was found. Hypomagnese-
mia was more signiﬁcantly frequent (p< 0.05) in moderate
and severe chronic asthmatic patients. Also, a statistically sig-
niﬁcant decrease in serum magnesium level was found in pa-
tients with acute attacks in comparison with chronic stable
asthma. This is in agreement with the study by Chaiwat and
Poonkasem [21]. Omer, [18] also, noticed that the number of
hospitalizations in asthmatics with low Mg levels was 40%,
compared to 12% in asthmatics with normal Mg levels.
Although the effect of hypomagnesemia in patients with
chronic asthma was unknown and the occurrence of hypomag-
nesemia in asthmatics was not fully explained but, some earlier
reports showed an association between magnesium deﬁciency
and an increased airway hyper reactivity [22], The evidence
suggests that magnesium ions participate in numerous bio-
chemical and physiologic processes that directly inﬂuence lung
function and respiratory symptoms. The mechanisms for ef-
fects of Mg on lung function include alteration in ASM func-
tion [23], immune function [24] and oxidative stress [25].
Hypomagnesemia may also increase the neuromuscular irrita-
bility, thus making a few individuals more susceptible to the
bronchial spasms [26]. Low dietary magnesium was also found
to be associated with wheezes and impairment of lung function
in normal subjects [27], while magnesium supplementation can
reduce asthma symptoms [28].
Hypokalemia was found in 42% of our cases with stable
bronchial asthma. These ﬁndings were closely similar to theﬁndings reported by several studies [20,29]. On the other hand,
we noticed that more patients with acute asthma exacerbation
(54%) had hypokalemia and, there was a signiﬁcant decrease
in potassium level in these patients than those with stable
bronchial asthma. Robert et al. [30] reported hypokalemia in
64% of children with asthmaticus status. This can be explained
by the signiﬁcant decrease in magnesium level as Whang et al.
[31] reported that magnesium depletion often causes hypokale-
mia (due to hypomagnesemia causing impaired Na/K ATPase
activity, impaired K–Na–Cl-co-transport and increased efﬂux
through K channels, which in turn lead to an increased renal
potassium loss.
Hypokalemia may also occur due to active inhibition of
potassium secretion in the cortical collecting tubule, possibly
caused by the stimulation of membrane sodium potassium-
dependent adenosine triphosphatase that results in hyper
polarization of the cellular membrane potential [32].
Recently, the results of Vittal et al. [26] study indicated that
serum electrolytes like magnesium, potassium and phosphate
decreased signiﬁcantly in patients with acute severe asthma
who were on treatment with nebulized salbutamol. The mech-
anism and clinical signiﬁcance of these ﬁndings are unclear and
they warrant further studies
In the present study, all stable asthmatic patients had nor-
mal serum ionized calcium (with the mean level 1.1 ± 0.19).
These results are similar to the results of Emad et al. [20]
and Omer [18] who reported that all stable asthmatic patients
had a normal serum calcium level and explained this ﬁnding as
none of asthmatic patients were receiving IV b2-agonists or IV
aminophylline that cause an increase in the urinary excretion
of calcium during the measurement of their serum electrolytes
[13].
On the other hand, the current study revealed that there
was a high frequency of hypocalcemia in asthmatic patients
during acute exacerbation (22%). Knusten et al. [33] docu-
mented that hypocalcaemia occurred as a result of increase
in urinary excretion of calcium in asthmatic patients treated
with IV aminophylline, while patients in the current study
did not receive IV aminophylline therapy.
Another explanation is related to magnesium when it is
deﬁcient, the action of calcium is enhanced and an excess of
magnesium blocks calcium. These interactions are important
to the patient with respiratory diseases because the intracellu-
lar inﬂux of calcium causes bronchial smooth-muscle contrac-
tion [34].
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ble link between vitamin D and asthma. Further clariﬁcation
of the role of vitamin D in the lung functions and immunity
may hold profound implications for the prevention and treat-
ment of asthma [35].
The present work conﬁrmed that incidence of hyponatre-
mia is low (4%) in stable asthmatic patients and this is consis-
tent with the results of Omer, [18] who reported hyponatremia
in 4.3% of patients with stable bronchial asthma. This may be
related to the fact that theophylline increases production of ur-
ine and enhances excretion of water and electrolytes [36].
Although the total number of patients with chronic asthma
and low serum sodium levels was too small to draw a clear
conclusion about its prevalence and clinical signiﬁcance, fur-
ther studies with a larger number of subjects are needed to
evaluate the signiﬁcance of this ﬁnding.
In group II patients, no abnormalities were noted in serum
sodium level which is consistent with the results of Potter &
Klein, [37] who studied 20 children during severe attacks of
acute asthma and found that serum sodium concentrations
on admission were within normal ranges.
In the present study, the therapeutic drugs administered for
the management of asthma were found to have an effect on the
serum magnesium and potassium levels. Hypokalemia and
hypomagnesemia were more prevalent among asthmatics that
received b2-agonist in either monotherapy or combined with
steroid and or theophylline (Table 3).
Contrary to our results, Omer, [18] noticed in his study,
that there was no effect of therapy (inhaled b2-agonists, in-
haled steroids, and oral theophylline) on serum electrolyte lev-
els in patients with chronic asthma. He concluded that the
underlying cause of hypomagnesemia in patients with chronic
asthma remains unclear and further studies may be needed.
In previous studies, the cause of hypomagnesemia in pa-
tients with acute asthma has been related to the use of b2-ago-
nists either orally [38] or IV, [39] or by nebulization [40], rather
than by inhalation. Treatment with b2-agonists can reduce ser-
um magnesium levels through urinary loss or intracellular
shift. Omer, [18] noticed the increased urinary excretion of
Mg, was secondary to therapy whatever b2-agonist, steroids,
and or xanthines were used for management of asthma.
For chronic asthma, there were few studies to evaluate the
prevalence of hypokalemia in patients with chronic asthma
receiving inhaled steroids and b2-agonists. Administration of
b2-agonists can cause hypokalemia through increased cellular
inﬂux of potassium, mediated by b2 stimulation of membrane
sodium potassium-dependent adenosine triphosphatase
[41,42].
b2-agonist can also enhance reduction of serum potassium
by concomitant theophylline treatment [7]. It was reported that
theophylline can lead to alteration in the serum potassium level
which may be due to beta adrenergic action caused by the stim-
ulation of adenylate cyclase increasing cAMP level which in
turn enhances Na+/K+ ATP-ase activity resulting in a shift
in the K+ from extracellular into intracellular ﬂuid. In addi-
tion, theophylline increases the production of urine and en-
hances excretion of water and electrolytes [36].
As regards the effect of magnesium sulfate infusion on
functional parameters; the present study revealed that there
was a signiﬁcant increase in FEV1, PEFR which is consistent
with Rolla et al. [43] and Devi et al. [44]. On the other hand,
Mohammed and Goodacre [45] found weak evidence thatintravenous magnesium sulfate improves respiratory function
in adults. But, of particular relevance and concern is the fact
that the studies varied in whether patients with existing pul-
monary pathology (such as chronic obstructive pulmonary dis-
ease) were excluded from the study.
Alter et al. [46] identiﬁed seven adult and two pediatric tri-
als and found that magnesium sulfate was associated with a
signiﬁcant improvement in spirometric airway function by
16% of a standard deviation, but concluded that the clinical
signiﬁcance of this effect was uncertain. Cheuk et al. [34]
undertook a meta-analysis of ﬁve trials in children and con-
cluded that intravenous magnesium sulfate was effective in
reducing hospital admissions, and improving pulmonary func-
tion tests and clinical symptoms.
The mechanisms of action of magnesium on respiratory air-
ways are multiple and include relaxation of airway smooth
muscle, bronchodilatation, anticholinergic effect, and stabil-
ization of the mast cells [14].
In contrast, to our study, short-term magnesium supple-
mentation trials to assess the effects of supplemental magne-
sium on lung function and symptoms among patients with
asthma by Mohamed [35] have had mixed results. A high mag-
nesium intake was associated with improvement in asthma
symptoms, though not in measures of airﬂow or airway reac-
tivity [47].
Conclusion
Hypomagnesemia and hypocalcemia were found to be the two
most common electrolyte disturbances in patients with chronic
stable asthma and also in those with acute asthma exacerba-
tion. Therapeutic agents used to treat patients with bronchial
asthma have a role on abnormal electrolyte levels.
Recommendation
A shortcoming of this study is that intracellular levels of elec-
trolyte were not considered. It is important to remember that
serum electrolyte levels, mainly magnesium and potassium,
may not correctly reﬂect their intracellular levels. Skeletal mus-
cle biopsies of asthmatics had lower magnesium and potassium
concentrations compared with healthy controls, both with and
without oral beta 2-agonists therapy [48]. Whether the ﬁndings
are related to asthma pathophysiology or treatment needs fur-
ther investigations. The evaluation of intracellular electrolyte
levels in ASM is technically difﬁcult and additional studies
are desirable to explore it.
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